Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions
<p>So far, in the advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status, the treatment remmendations has reached an agreement: for patients with EGFR mutation-positive, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)...
שמור ב:
Main Authors: | Caixia Deng (Author), Hu Luo (Author), Xiangdong Zhou (Author) |
---|---|
פורמט: | ספר |
יצא לאור: |
Open Journal of Cell and Protein Science - Peertechz Publications,
2018-10-01.
|
נושאים: | |
גישה מקוונת: | Connect to this object online. |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
פריטים דומים
-
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
מאת: Isla D, et al.
יצא לאור: (2016) -
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
מאת: Yamin Shu, et al.
יצא לאור: (2022) -
EGFR mutation testing in non-small cell lung cancer (NSCLC)
מאת: Fouad Al Dayel
יצא לאור: (2012) -
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
מאת: Walleser S, et al.
יצא לאור: (2012) -
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
מאת: Cong Xu, et al.
יצא לאור: (2023)